Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (65)	12/20/2004 3:29:58 AM
From: capstone	Read Replies (1) \| Respond to of 588

I am long Acadia, but two things that worry me are (1) the IP position for 104, and (2) the possibly declining need for 103 given the emerging 3rd generation of drugs like Abilify which have much less side effects. On 104, composition of matter is not attainable and they have filed for a use patent. There is one issued use patent already relating to analgesia. I'm not wild about hanging my hat on a use patent -- and even then one that has not issued. On 103, a drug like that would have been a blockbuster 15 years ago. But everyone and his uncle is trying to bring more sophisticated drugs to market that don't cause the weight gain, akathisia, etc. And Abilify is likely the tip of the iceburg. Comments anyone?